Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy. - Wikidata - wikimedia - TriplyDB

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

http://www.wikidata.org/entity/Q33862927

about

Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.The pursuit of oncotargets through understanding defective cell regulation Characterization of lung cancer by amide proton transfer (APT) imaging: an in-vivo study in an orthotopic mouse model UDP-glucuronosyltransferase 1A determinates intracellular accumulation and anti-cancer effect of β-lapachone in human colon cancer cells Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR pathway.Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.Prodrug strategy to achieve lyophilizable, high drug loading micelle formulations through diester derivatives of β-Lapachone.Afatinib and its encapsulated polymeric micelles inhibits HER2-overexpressed colorectal tumor cell growth in vitro and in vivo Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.Hydroxycamptothecin-loaded Fe3O4 nanoparticles induce human lung cancer cell apoptosis through caspase-8 pathway activation and disrupt tight junctions.SoNar, a Highly Responsive NAD+/NADH Sensor, Allows High-Throughput Metabolic Screening of Anti-tumor Agents.RETRACTED: NAD(P)H:quinone oxidoreductase 1 protects lungs from oxidant-induced emphysema in mice.Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging.Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC.Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy.An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis Esterase-activatable β-lapachone prodrug micelles for NQO1-targeted lung cancer therapy.NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer.Molecular-targeted nanotherapies in cancer: enabling treatment specificity.Exploring polymeric micelles for improved delivery of anticancer agents: recent developments in preclinical studies.Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments.Drug delivery and nanodetection in lung cancer.Nanotechnology-enabled delivery of NQO1 bioactivatable drugs.Recent updates in utilizing prodrugs in drug delivery (2013-2015).Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.Synthesis and antitumor activity of selenium-containing quinone-based triazoles possessing two redox centres, and their mechanistic insights.Preclinical Pharmacokinetic Evaluation of β-Lapachone: Characteristics of Oral Bioavailability and First-Pass Metabolism in Rats.Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species.Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity.Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.Lysosome-oriented, dual-stage pH-responsive polymeric micelles for β-Lapachone delivery.A Tumor-Specific Cascade Amplification Drug Release Nanoparticle for Overcoming Multidrug Resistance in Cancers.Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis.Enhancing Oral Absorption of β-Lapachone: Progress Till Date.PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs.Encapsulation of nor-β-lapachone into poly(d,l)-lactide--glycolide (PLGA) microcapsules: full characterization, computational details and cytotoxic activity against human cancer cell lines

P2860

Q27346846-BBB35B66-68E3-4BF1-8F46-1B07526ED151 Q28395166-75D0FF1E-B914-4EFC-8B35-D130F2D31805 Q28534416-875CE920-8D7C-445A-9A38-DB39AE4F58BB Q28543502-9EC19D4E-2398-4E4D-8D79-AF2CCE8EFFF5 Q30583249-226697D6-3B8C-4801-8F23-38AF4C65F947 Q33767952-6F214D6F-C260-4EB2-A4A8-F23D88F6A183 Q34047248-0BFDDC6E-DA96-49F4-B56F-DAB84C256F3A Q34104079-0CD1B0D5-A062-4787-9F02-79CCC751E5A6 Q34227677-DBDC959D-3050-4D5B-B16F-DBA8D23B40B0 Q34995515-6DA473C0-AE74-43CD-8396-3F6900ABE0D6 Q35593948-84D45CC8-984C-42E5-A328-E3BCC6C7986A Q35705835-15A7FCA7-6034-402B-AA54-8F9F16FF14B4 Q35856376-C783FABA-8A5B-44C6-BED7-72CBBF6BDCAA Q36316513-8FE9DFCC-5BCF-4C83-B683-2AE20D15DC9E Q36471467-180F7367-F265-4623-B904-C5106FBC6BBC Q36619072-DB9ED58C-9FF0-458B-8F72-0807A5CE4A24 Q36695591-0DFA751D-858E-4CD9-8432-D3ABAA3B60D1 Q36716649-7CB2B20D-EB6E-44D9-9C1C-81D8CA5871BF Q37440695-D820A1A5-8737-45D2-9317-C970FF23CAC7 Q37954497-5DA4FC05-9AA8-4D55-9C62-EF2C1CA7C5BB Q38168377-146D5281-652A-4CD8-838F-8F07364B27C5 Q38191981-F976F0D3-FC72-427F-9F4E-AF335BA6CB87 Q38247299-EC89B37E-BB6B-4327-8F3C-71BCD82B7C13 Q38267035-85799F1F-9871-453B-A4DC-C1DCD19C0B9C Q38603364-931E540D-673B-40CF-A399-0D67E9E27347 Q38702949-18B2DDD2-15C5-4F83-A76A-D2BE0492CAB2 Q38726394-352409FE-F470-4C1B-9BA7-36C9CCA30883 Q38762468-840B1DF6-05EC-4DE0-9455-851CD4F24081 Q39004214-17E393AC-8B4E-4705-89D4-22054AFDB961 Q39099843-5D4886F8-EE44-470A-9E67-BEFDD7DDAD38 Q39617420-F80DDD25-BA33-4B60-B192-58ECC03E6C63 Q42409402-535BB096-1B38-45AF-8DE2-41E927C92554 Q46086889-07F73DD7-BDB5-421E-9A34-5E7F62E9DF55 Q46317390-B2B52BC4-2BB6-4D35-ABB4-CAB2929AD762 Q47165034-1B74491D-39D8-4AC0-B308-4841027C6EA6 Q49108416-38454001-4AE5-4CA0-BA80-E39C9AC13EF8 Q50233354-D366AFC5-C52F-4D4C-B800-3357CC721F34 Q57150128-16BCB1E6-2B40-4D82-9E13-94C8DC3D7FB9

P2860

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

http://www.wikidata.org/entity/Q33862927

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

@ast

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

@en

type

label

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

@ast

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

@en

prefLabel

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

@ast

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

@en

P1433

Q33862927-1F657B33-C366-47F4-98D3-434688FF03AB

P1476

Q33862927-7F951CF0-FAC4-48D6-BF68-3ED89E119F37

P2093

Q33862927-2347DD26-E1B6-4F70-A447-C4FB3EDE2114

Q33862927-264B98D6-9D69-4B07-89AA-F0BA4FA84723

Q33862927-5631B453-1C31-4261-B8C5-A2BAE7A6E6AA

Q33862927-7930A7F8-8F60-4E00-86D1-FDB133B18381

Q33862927-89DC0491-BFA1-4758-8AF2-5EE0DA60D853

Q33862927-A21F9B26-C942-4123-BCD8-BF71B7D77901

Q33862927-A38F39C4-1537-412A-9958-2A8814E3C23F

Q33862927-D873C167-D8A1-4502-AB17-92D8072FC137

Q33862927-DAEBA9A8-D008-499F-A5C3-6918CF4CE842

Q33862927-E30E72C0-55BB-46F2-ABB6-EE18E9074CB8

P2860

Q33862927-039D2DF6-60DF-4C0E-8308-ED99D56C663D

Q33862927-04A57B91-3CF0-4C8F-9160-32FA6DB37487

Q33862927-08385218-8544-4BA6-8506-A60B958F1E38

Q33862927-27F8D963-5A69-455F-BAA4-A178E2EA92C1

Q33862927-2803C3EE-97DA-4A89-86F9-29AAED8C8B53

Q33862927-35202E41-AD65-4C40-A0EB-CD8F75996E06

Q33862927-3ED0BE71-056A-4B84-B9B2-55FEF3B77220

Q33862927-41565389-92B9-4756-AD95-BE4A1E562E04

Q33862927-4C9E2A93-C1C0-47A8-A77B-E7EC7F0B07F0

Q33862927-5057A0D0-BDB4-4914-ADF2-9D00BA7A83B4

P304

Q33862927-93F77A00-E1F4-4AAF-B191-0A459868E464

P31

Q33862927-A32C52AF-2DEE-4E7D-AD80-9505B1DBB20D

P356

Q33862927-CF026C19-412E-4798-A309-7F3D31EF1C92

P407

Q33862927-8BBB6437-8B29-4BF2-9080-E19C7CC21744

P433

Q33862927-2BE3277A-68C2-4249-A76C-2B58A85FBCB7

P478

Q33862927-812FFD12-54B9-4316-BC79-33C43F02E900

P50

Q33862927-a064d950-4b46-805f-cbd2-1ae6e7c1cdd1

P577

Q33862927-56443079-0C2A-4618-AA0F-FA9078A0C024

P698

Q33862927-515765C6-4D5A-43C5-897A-66724A3A4169

P932

Q33862927-F1E70F70-CC4E-4026-8255-AC52FBC0C35B

P356

0008-5472.CAN-09-3995

P1433

Cancer Research

P1476

Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.

@en

P2093

Chalermchai Khemtong

http://www.w3.org/2001/XMLSchema#string

Chase W Kessinger

http://www.w3.org/2001/XMLSchema#string

David A Boothman

http://www.w3.org/2001/XMLSchema#string

Erik A Bey

http://www.w3.org/2001/XMLSchema#string

Huabing Chen

http://www.w3.org/2001/XMLSchema#string

Jagadeesh Setti-Guthi

http://www.w3.org/2001/XMLSchema#string

Jinming Gao

http://www.w3.org/2001/XMLSchema#string

Kevin A Carnevale

http://www.w3.org/2001/XMLSchema#string

Su-Geun Yang

http://www.w3.org/2001/XMLSchema#string

William G Bornmann

http://www.w3.org/2001/XMLSchema#string

P2860

Openings between defective endothelial cells explain tumor vessel leakiness

Cancer statistics, 2009

Cancer nanotechnology: opportunities and challenges

Nanocarriers as an emerging platform for cancer therapy

Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review

Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery.

Noninvasive in vivo monitoring of methemoglobin formation and reduction with broadband diffuse optical spectroscopy.

In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles.

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

Micellar nanocontainers distribute to defined cytoplasmic organelles.

P304

3896-3904

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-09-3995

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20460521

http://www.w3.org/2001/XMLSchema#string

P932

2873165

http://www.w3.org/2001/XMLSchema#string